SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy

BACKGROUND: SARS-CoV-2 enters cells by binding of its spike protein to angiotensin-converting enzyme 2 (ACE2). Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have been reported to increase ACE2 expression in animal models, and worse outcomes are reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Mina K., Karnik, Sadashiva, Saef, Joshua, Bergmann, Cornelia, Barnard, John, Lederman, Michael M., Tilton, John, Cheng, Feixiong, Harding, Clifford V., Young, James B., Mehta, Neil, Cameron, Scott J., McCrae, Keith R., Schmaier, Alvin H., Smith, Jonathan D., Kalra, Ankur, Gebreselassie, Surafel K., Thomas, George, Hawkins, Edward S., Svensson, Lars G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415847/
https://www.ncbi.nlm.nih.gov/pubmed/32771682
http://dx.doi.org/10.1016/j.ebiom.2020.102907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415847/
https://www.ncbi.nlm.nih.gov/pubmed/32771682
http://dx.doi.org/10.1016/j.ebiom.2020.102907

Ejemplares similares